December 7, 2020 -- MilliporeSigma is increasing its manufacturing footprint in the U.S. with a $47 million investment in its Danvers, MA, and Jaffrey, NH, biomanufacturing facilities.
The expansions will increase capacity and output in 2021 (MA) and 2022 (NH) and create 700 new manufacturing positions. These sites will supply critical products to customers for the development and manufacturing of therapies, including COVID-19 vaccines.
The Danvers expansion will add 65,000 sq ft of single-use assembly operations to the existing 120,000-sq-ft facility. This will support MilliporeSigma's Mobius single-use consumables production. The total investment in about $25 million and will add approximately 400 jobs throughout 2021.
The Jaffrey expansion will add 25,000 sq ft to the existing 260,000-sq-ft facility. The additional capacity will include new production lines and equipment and support production of filtration devices and membrane products, namely, Durapore filters, Express filters, and Viresolve products that are used to remove viral contamination during therapeutic production. The total investment in Jaffrey is $22 million and will bring 275 jobs by 2022.